Effects of MitoQ on mobility and cognitive performance in frail older adults
Official title: The Mito-Frail Trial: Effects of MitoQ on Vasodilation, Mobility and Cognitive Performance in Frail Older Adults
Run by UConn Health · NCT06027554 · Data updated 2026-11-12
This study is testing if a supplement called MitoQ can help frail older adults aged 65-80 improve their walking and thinking abilities compared to a placebo.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Ages | 65 Years to 80 Years |
| Sex | All |
| Enrollment | 60 (estimated) |
| Sponsor | UConn Health Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Farmington, Connecticut) |
| Status | Recruiting |
| Started | October 7, 2024 |
| Main results expected | March 1, 2027 |
| Study ends | February 1, 2028 |
| Registry record updated | August 12, 2026 |
| Trial ID | NCT06027554 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are men and women aged 65-80 with slow gait speed and/or mild cognitive impairment who are in good cardiovascular health.
✕Probably not a fit
Patients with recent infections, severe autoimmune diseases, or those on blood thinners may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This clinical trial investigates the impact of MitoQ supplementation on vascular function, oxidative stress, and both physical and cognitive performance in frail older adults aged 65-80. The study aims to compare these factors between participants with slow gait speed and mild cognitive impairment. By targeting the shared mechanisms of aging and chronic conditions, the trial seeks to enhance mobility and cognitive capabilities in this vulnerable population. Participants will receive either MitoQ or a placebo to assess the potential benefits of this intervention.
Why it matters
Potential benefit: If successful, this trial could improve mobility and cognitive function in frail older adults, potentially enhancing their quality of life and independence.
How similar studies have gone: While some studies have explored interventions for frailty and cognitive decline, the specific approach of using MitoQ in this context is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * men and women aged 65-80 with a slow gait speed (0.4m/s based on a 4m walk) and/or mild cognitive impairment. * good cardiovascular health (not taking any blood pressure/flow/metabolism altering medications) Exclusion Criteria: * A vaccination in past two weeks * Recent acute infection three weeks prior to enrollment * Known immunodeficiency (including HIV infection, primary immunodeficiency, any history of chemotherapy or radiotherapy * Use of medicines during past 6 months known to alter immune response such as high- dose corticosteroids * Severe autoimmune disease requiring biological therapy * Major severe illness and/or Hospitalization in past 3 months * On warfarin or other medications that are considered a blood thinner * Recent fall or other conditions that will impair ability to complete and/or interpret mobility performance test * Known bleeding disorder * Any conditions that would impair the function to perform grip strength test * include advanced neurological disease, severe co-morbid disease, terminal illness with reduced life expectancy, severe disability, unintentional weight loss in last 12 months and participation in another study. * Diabetes patients requiring insulin (For reducing the risk that participants will have hypoglycemic episodes when fasting for study visits) * Baseline ECG QTc \>450 ms in men and QTc \>460 ms in women * Prior diagnosis of ventricular arrhythmia (e.g., ventricular tachycardia, ventricular fibrillation, torsades de pointes)
Where it's running
-
UConn Health
Farmington, Connecticut, United States Recruiting
Study contacts
- Principal investigator: Oh Sung Kwon, PhD — University of Connecticut
- Study coordinator: Oh Sung Kwon, PhD
- Email: ohsung.kwon@uconn.edu
- Phone: 860-486-1120
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Longevity Metrics AI/ML Development Study
Researchers are testing AI models that score health screening tests and predict outcomes like life expectancy for adults, using ongoing follow-up data.
-
Acupoint Stimulation and Exercise for Pre-frail Older Adults in Taiwan
This study tests whether combining exercise with daytime and sleep-improving acupoint stimulation helps pre-frail adults 50 and older in Taiwan feel less frail and sleep better.
-
Centenarian cohort in Navarre to study aging and longevity
This study tests what factors help centenarians in Navarre stay healthier as they age and what might explain their exceptional longevity.
-
Health Ahead: Comparing AI vs. Humans for Preventive Health Screening
This study tests AI-assisted screening interpretation against human-only reads to see if automated screening can match or improve current practice for adults, especially in underserved areas.
-
How environment and biology together predict health, aging, and death
Researchers are following adults to see how living conditions and biology together relate to aging and life expectancy, by linking personal health data with environmental and social information over time.
-
100-Year Human Aging and Longevity Tracking Program
This project will follow adults over their lifetimes to see if repeated health tests can predict lifespan, causes of death, serious disease, and loss of function.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.